0001628280-21-023169.txt : 20211112 0001628280-21-023169.hdr.sgml : 20211112 20211112161812 ACCESSION NUMBER: 0001628280-21-023169 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211109 FILED AS OF DATE: 20211112 DATE AS OF CHANGE: 20211112 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Martin Michael Robert CENTRAL INDEX KEY: 0001837647 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36421 FILM NUMBER: 211403786 MAIL ADDRESS: STREET 1: #1203-4464 MARKHAM STREET CITY: VICTORIA STATE: A1 ZIP: BC V8Z7X8 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aurinia Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001600620 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: #1203-4464 MARKHAM STREET CITY: VICTORIA BC STATE: A1 ZIP: V8Z 7X8 BUSINESS PHONE: 250-708-4272 MAIL ADDRESS: STREET 1: #1203-4464 MARKHAM STREET CITY: VICTORIA BC STATE: A1 ZIP: V8Z 7X8 4 1 wf-form4_163675187710828.xml FORM 4 X0306 4 2021-11-09 0 0001600620 Aurinia Pharmaceuticals Inc. AUPH 0001837647 Martin Michael Robert #1203-4464 MARKHAM STREET VICTORIA A1 V8Z7X8 BRITISH COLUMBIA, CANADA 0 1 0 0 Chief Business Officer Common Shares 2021-11-09 4 S 0 50000 30.17 D 126861 D Common Shares 2021-11-10 4 S 0 50000 31.26 D 76861 D Common Shares 2021-11-10 4 S 0 10000 30.55 D 66861 D Common Stock 2021-11-11 4 M 0 29000 18.38 A 95861 D Common Stock 2021-11-11 4 S 0 29000 28.82 D 66861 D Common Shares 2021-11-11 4 S 0 11000 29.50 D 55861 D Stock Option (right to buy) 18.38 2021-11-11 4 M 0 29000 0 D 2030-01-28 Common Stock 29000.0 27900 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $30.00 to $30.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $31.00 to $31.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $30.30 to $30.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $28.60 to $29.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The shares subject to the option vest in thirty-six equal monthly installments from the grant date. /s/ Michael Robert Martin 2021-11-12